Ann: Core patent granted in Australia , page-19

Hi Wayne,

Thanks.

You wrote...

I understand that biological payloads would include antibodies. Genentech, having spent a couple of years in collaboration with Phylogica, are discussing a deal in relation to our 2nd generation libraries. Do you think that the progression in the collaboration is evidence that the CPPs offer an improvement in delivery and capability compared to the bispecific antibody?

As you mentioned, not only are Genetech evaluatating the 1st generation BBBP's, but have progressed to discussions for 2nd generation libraries for BBBP's. As mentioned in one of my earlier posts, I don't think Phylogica are quite there yet but Genentech must certainly like the platform. This is an excellent endorsement and a significant step forward in the collaboration imo.

Regards,
Tony